Lawyer C, Pai S, Watabe M, Bakir H, Eagleton L, Watabe K
Depariment of Internal Medicine Pulmonary Division, Southern Illinois University, Springfield 62702, USA.
J Antimicrob Chemother. 1996 Mar;37(3):599-604. doi: 10.1093/jac/37.3.599.
We have synthesized a C-terminal portion of tracheal antimicrobial peptide (TAP) with 38 amino acids and tested it for efficacy on various clinical isolates of Pseudomonas aeruginosa strains from patients with cystic fibrosis and also on Aspergillus fumigatus. Our results indicate that the synthetic TAP has both potent bactericidal and fungicidal activities and that a combination of TAP and amphotericin B showed strong additive effects of growth inhibition on A fumigatus. These results suggest that TAP is potentially an effective therapy for Aspergillus and multi-drug-resistant Pseudomonas, pathogens that are often a serious threat to patients with cystic fibrosis.
我们合成了一种含有38个氨基酸的气管抗菌肽（TAP）的C末端部分，并测试了其对来自囊性纤维化患者的各种铜绿假单胞菌临床分离株以及烟曲霉的疗效。我们的结果表明，合成的TAP具有强大的杀菌和杀真菌活性，并且TAP与两性霉素B的组合对烟曲霉显示出强烈的生长抑制相加作用。这些结果表明，TAP可能是治疗曲霉和多重耐药铜绿假单胞菌的有效疗法，这些病原体通常对囊性纤维化患者构成严重威胁。
